October 16, 2017 Licensing, IP, and Legal PR/Corporate Product Launch

Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS

Basel, 16 October 2017 Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS Largest body of OCREVUS data presented at a congress to date reinforce favourable benefit-risk profile and advance clinical understanding of disease progression Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today... Read more

September 28, 2017 Licensing, IP, and Legal

Roche’s OCREVUS (ocrelizumab) approved in Switzerland for primary progressive and relapsing forms of multiple sclerosis

Basel, 28 September 2017 Roche’s OCREVUS (ocrelizumab) approved in Switzerland for primary progressive and relapsing forms of multiple sclerosis OCREVUS is the first and only approved treatment for people with primary progressive MS, a highly disabling form of MS An important new treatment option for people with relapsing forms of MS demonstrating superior efficacy on... Read more

September 27, 2017 Clinical Research/Diagn. Licensing, IP, and Legal

Oxford Immunotec Announces Update in Patent Infringement Litigation

OXFORD, United Kingdom and MARLBOROUGH, Mass., September 27, 2017 (GLOBE NEWSWIRE) — Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced a decision of the U.S. District Court for the District of Massachusetts in the Company’s patent infringement... Read more

September 27, 2017 Lab Top-10 Licensing, IP, and Legal

Thermo Fisher Scientific to Participate in Capitol Hill Briefing on Precision Medicine Advancements

Thermo Fisher Scientific to Participate in Capitol Hill Briefing on Precision Medicine Advancements CARLSBAD, Calif., Sept. 27, 2017 /PRNewswire/ — Thermo Fisher Scientific, the world leader in serving science, today announced it will participate in a Capitol Hill briefing hosted by AdvaMedDx and LUNGevity Foundation to discuss leading developments in medical diagnostics that are shaping... Read more

September 27, 2017 Atomic Spectroscopy Licensing, IP, and Legal M&A, Partnerships Microscopy

CHU Sainte-Justine Research Center opens cutting-edge microscopy platform in partnership with Leica Microsystems

Left to right: Elke Küster-Schöck, Lianne Dale, Gilles Hickson, Graziella Di Cristo, Jacques L. Michaud, and Wayne England. This platform is the latest of Leica Microsystems’ partnerships with research facilities across the world dedicated to helping top academic institutions provide tools that accelerate scientific discovery. The platform houses 11 state-of-the-art imaging systems from simple epi-fluorescence... Read more

September 22, 2017 Bio/Pharma/CRO Licensing, IP, and Legal

Roche receives EU approval of TECENTRIQ® (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer

Basel, 22 September 2017 Roche receives EU approval of TECENTRIQ® (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer TECENTRIQ provides a new treatment option for people with previously treated locally advanced or metastatic non-small cell cancer (NSCLC) TECENTRIQ is a new treatment option for people with metastatic... Read more

September 22, 2017 Bio/Pharma/CRO Licensing, IP, and Legal

Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma

Basel, 22 September 2017 Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma Approval is based on phase III GALLIUM study results, which showed superior progression-free survival for Gazyva/Gazyvaro compared to MabThera/Rituxan Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Gazyvaro® (obinutuzumab) in combination... Read more